GlassScriptPhysician profile
Cindy Laing
NPI 1033606876
$3,157.46
in general payments reported to CMS, 2019-2025
26 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.70 · 2021: $80.29 · 2022: $475 · 2023: $785 · 2024: $910 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $463.34 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $363.23 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $261.96 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.77 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $232.40 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $164.22 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $146.86 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $142.28 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $127.30 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.69 | 2022-2025 | Xifaxan |
| Corcept Therapeutics | $122.09 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $122.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $110.27 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Dexcom, INC. | $101.95 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $77.28 | 2023-2025 | Repatha, Otezla, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $70.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $51.62 | 2022-2023 | Spravato |
| Mylan Specialty L.P. | $37.58 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $34.59 | 2024-2025 | Voquezna |
| Medtronic, INC. | $32.40 | 2025 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $24.83 | 2025 | Inspire |
| Smith+Nephew, INC. | $20.48 | 2024 | Collagenase Santyl |
| Bayer Healthcare Pharmaceuticals INC. | $19.37 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.27 | 2025 | Uptravi, Opsumit |
| Currax Pharmaceuticals LLC | $16.13 | 2025 | Contrave |
| E.R. Squibb & Sons, L.L.C. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Laing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.